Stocktoria
BioNexus Gene Lab Corp BGLC
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2020-03-11
BioNexus Gene Lab Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 14.6% | 13.6% | 13.6% | 11.5% | 17.0% | 15.1% | 44.0% | 13.5% |
| Operating margin | -39.9% | -16.5% | -26.5% | -2.7% | 7.9% | 11.2% | -217.2% | 28.2% |
| Net margin | -40.2% | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% | -194.1% | 12.5% |
| FCF margin | -25.3% | -24.4% | -20.2% | 5.0% | 0.0% | 1.2% | -181.2% | -110.4% |
| Return on assets | -32.3% | -15.3% | -23.1% | -4.1% | 7.8% | 10.8% | -20.0% | 1.6% |
| Return on equity | -34.6% | -19.2% | -27.2% | -5.3% | 10.5% | 16.4% | -22.0% | 1.7% |
| Current ratio | 10.46 | 3.81 | 4.93 | 3.00 | 3.07 | 2.37 | 17.11 | 20.64 |
Source: SEC EDGAR filings · CIK 0001737523 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.